Chronos-3 trial results : Aliqopa, rituximab combo meets primary endpoint of PFS, says Bayer

Chronos-3 trial results : Bayer said that the investigational combination of Aliqopa (copanlisib) and rituximab considerably increased progression-free survival (PFS) in patients having relapsed indolent ... Read More